Bone Health in Rheumatoid Arthritis: An Update

Area of Science:

• Rheumatology
• Osteoporosis Research
• Bone Metabolism

Background:

• Rheumatoid arthritis (RA) affects 1% of the global population, presenting as the most common inflammatory arthritis.
• RA is a major risk factor for secondary osteoporosis (OP), leading to bone loss at periarticular, marginal, and systemic levels.
• Understanding osteoclast-mediated bone loss in RA is crucial for developing targeted interventions and identifying at-risk individuals.

Purpose of the Study:

• To review recent advances in understanding RA-associated bone loss mechanisms.
• To discuss the skeletal effects of current RA and anti-osteoporosis therapies.
• To highlight future research directions for optimizing bone health management in RA patients.

Main Methods:

• Literature review of recent advances in RA and osteoporosis.
• Analysis of current therapeutic strategies for RA and bone loss.
• Identification of evidence gaps and areas for future research.

Main Results:

• Controlling RA disease activity and inflammation is fundamental for bone loss management.
• Current therapies and their skeletal effects in RA patients are discussed.
• Significant evidence gaps persist, including lack of RA-specific fracture risk thresholds and comparative trials for bone protective agents.

Conclusions:

• RA-associated bone loss contributes substantially to morbidity, necessitating improved fracture risk stratification and standardized monitoring.
• Further research is required on biologic therapies' skeletal effects in men with RA and optimal DXA monitoring intervals.
• Addressing unmet needs in fracture risk assessment and treatment optimization is essential for advancing bone health in RA.